Windlas Biotech Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/c63eylepblcftjcoovxcv4ln.pdf

Key Takeaways


CDMO & Revenue Drivers

Windlass: "Our space is not to try to come and say that we are the cheapest and the largest. We try to go to the customers and say that we are upholding the quality. We are transparent, and we'll work with you for your needs."

Trade Generics & Institutional

Gupta: "The momentum has taken a hit, but that, I would say, is a temporary hit for a few quarters instead of a long-term listing. We are very confident of bringing back the momentum, bringing back good revenue numbers in this vertical."

Plant 6 & Capacity

Windlass: "Injectables was an expansion of our periphery because we entered a new dosage form. And therefore, that required some learning side from us also and customer also testing us and also a more complex dosage form."

Capacity Philosophy & Positioning

Gupta: "We don't think that having a huge plant facility would really do benefit us. We believe in having incremental capacity expansion... you become a little bit more desperate in terms of filling that huger plant than being able to focus... in terms of, be it operating working capital, or be it cash flows, or be it margins."

Costs, Working Capital & API Prices

Windlass: "The impression that I have in my mind is of volatility only. The stability is still to be there... I would be very incorrect to say that stabilization is already appear."

Exports & Other Verticals

Windlass: "I don't want to say that the tide has turned and pretend to know more than what anybody in the industry can say. But I think this is a welcome sign, and I want to -- we are honestly watching these growth numbers and definitely want to leverage them to the best of our ability."

Guidance & Commitments

CommitmentSpecificsTimeline
Plant 6 commercializationCapacity fully coming online at end of H1End of Q2 / end of H1 FY27, maybe 15 days plus/minus
Plant 6 depreciationExtra ₹3 crore per quarter startsQ3 FY27, with something in Q2 and Q3 it will be full
Trade Generics recoveryMomentum hit is temporary; confident of bringing back momentum and good revenue numbersA few quarters, not a long-term listing
Trade Generics codeine bridgeProgressively bridge the codeine gap as portfolio expands with new launches and replacementsNo specific date; progressive
Injectable capacity expansionWhen decision taken, 6–8 months to add machinery, qualify and bring online6–8 months from decision; decision not yet taken
Capacity beyond ₹1,100 croreCan further debottleneck existing facility to increase top line from current levelsNo date; after Plant 6 efficiencies
Next organic growth capexWill start working on another organic growth when extra capacities neededAfter increasing revenue from existing plants and Plant 6 efficiencies

Key Metrics

MetricQ1 FY27
Revenue₹248 crores, highest-ever quarterly revenue, +18% YoY
EBITDA (ex-ESOP)₹34 crores, +26% YoY; ESOP expenses of ₹7.2 crores excluded
EBITDA (reported)₹27 crores, including non-cash ESOP expenses of ₹7.2 crores
PBT (ex-ESOP)₹30 crores, +27% YoY
PAT (ex-ESOP)₹25 crores, +37% YoY
PAT (reported)₹18 crores, including non-cash ESOP expenses
EPS₹8.46
Generic Formulations CDMO revenue₹207 crores, +29% YoY
Trade Generics & Institutional revenue₹30 crores, following discontinuation of codeine-based products
Exports revenue₹11 crores, +79% YoY
Indian pharma market volume growth3.4% in Q1 FY27
Capacity utilization~65% currently; peak utilization for this business is 60–65%, stretchable to ~70%
Revenue capacity with Plant 6₹1,100 crores, with further ₹100–150 crores possible via debottlenecking
Plant 6 commercializationEnd of Q2 / H1 FY27, plus/minus 15 days
Expected quarterly depreciation increase from Plant 6~₹3 crores, plus/minus 10–15%, for initial 1 year, then declining